2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1221

Serum Uric Acid As an Independent Risk Factor on Progression of Chronic Kidney Disease in Gout Patients with Uric Acid Lowering Agent
Abstract Number: 129

Seven Joints Ultrasound Scoring System May be Useful and Effective in Assessing Disease Activity in Patients with Rheumatoid Arthritis in the State of Remission in Daily Clinical Practice
Abstract Number: 2158

Severe Neutropenia in Patients with Rheumatic Diseases at a Tertiary Care Hospital in South Korea
Abstract Number: 62

Severe Spine Osteoarthritis in Older Men Is Associated with the Risk of Incident Fragility Fracture
Abstract Number: 2943

Severity of Foot Pain Is Linked to the Prevalence of Depressive Symptoms: The Framingham Foot Study
Abstract Number: 189

Sex Differences in Characteristics, Utilization and Outcomes of Patient Undergoing Total Elbow Arthroplasty: A Study of the U.S. Nationwide Inpatient Sample
Abstract Number: 1072

Sex Ratio of Offspring Born to Women with Lupus and Rheumatoid Arthritis
Abstract Number: 1974

Sex Steroids, Interleukin-1, and Interleukin-10 Inhibit interferon–gamma (IFN-γ) Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Human Synovial Fibroblasts
Abstract Number: 2818

SH2 Domain-Containing Phosphatase 2 Promotes Aggressiveness of Rheumatoid Fibroblast-like Synoviocytes
Abstract Number: 617

Shared HLA Class I and II Alleles in Susceptibility to Ankylosing Spondylitis Among Three Ethnic Groups
Abstract Number: 2738

Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis
Abstract Number: 2611

Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non–radiographic Axial Spondylarthritis and ankylosing Spondylitis; Results from Turkbio Registry
Abstract Number: 1701

Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry
Abstract Number: 2603

Short-Term Non-Steroidal Anti-Inflammatory Drug (NSAID) Use Induces Subclinical-Kidney-Injury in Spondyloarthritis Patients: Urinary Biomarker Study
Abstract Number: 466

Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].